Monash Scientists Restore Memory in Alzheimer’s Mice, Cutting Amyloid-Beta 42% With Copper Drug
Updated
Updated · Starts at 60 · Jun 15
Monash Scientists Restore Memory in Alzheimer’s Mice, Cutting Amyloid-Beta 42% With Copper Drug
3 articles · Updated · Starts at 60 · Jun 15
Summary
Monash University researchers reported that a copper-based experimental drug restored memory and learning in Alzheimer’s-model mice, with cognitive performance improving about 44% versus untreated animals.
The treatment cut amyloid-beta buildup by 42% by reviving the brain’s waste-clearing pumps rather than attacking the toxic protein directly, according to the Nature Aging study.
Cu(ATSM) delivers small amounts of copper to repair those molecular pumps, which can fail over time and leave harmful proteins trapped in the brain.
Existing safety testing of the compound in other conditions could help speed a path to human trials, though researchers and outside experts cautioned that many animal results do not translate to patients.
More than 480,000 Australians live with dementia, and the findings add to efforts to find simpler, cheaper Alzheimer’s treatments amid doubts about the benefits of some anti-amyloid drugs.
A copper compound shows promise in mice. Could it finally be the breakthrough Alzheimer's treatment for humans?
Is fixing the brain's 'drainage system' the real key to defeating Alzheimer's disease?
Cu(ATSM) Restores Brain Clearance in Alzheimer’s: Preclinical Breakthrough and Path to Human Trials
Overview
Alzheimer's disease is marked by the buildup of harmful amyloid-beta proteins in the brain. Normally, the brain uses a clearance system, including P-glycoprotein (P-gp) pumps at the blood-brain barrier, to remove these proteins. In Alzheimer's, these pumps lose effectiveness, leading to impaired removal and the accumulation of toxic proteins, which clogs the brain's waste disposal system. Recent research highlights Cu(ATSM) as a promising therapy that restores P-gp function, helping the brain clear amyloid-beta more effectively. This approach targets the root cause of protein buildup, offering hope for improved memory and brain health in Alzheimer's patients.